Glaxo plc Reaches Settlement Agreement to Address Allegations of Unfair Business Practices

Summary

Glaxo plc has agreed to a consent agreement with the Federal Commission, which would require the company to divest its research and development assets for non-injectable migraine drugs within nine months, and obtain Commission approval for any future acquisitions of non-injectable migraine drug entities for the next ten years.